Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Their Variations as a Basis for a Prediction Model in Advanced NSCLC Patients Receiving Anlotinib

Table 4

Univariate analysis of factors associated with progression free survival and overall survival.

Prognostic factors	Patients	Progression free survival			Overall survival
		HR	95% CI	value	HR	95% CI	value
Age (years)
<65	91	1			1
≥65	61	0.936	0.673-1.300	0.693	0.914	0.634-1.319	0.632
Gender
Female	42	1			1
Male	110	1.091	0.762-1.560	0.635	1.373	0.907-2.078	0.134
Pathology
Squamous carcinoma and others	83	1			1
Adenocarcinoma	69	0.926	0.669-1.281	0.641	1.069	0.746-1.531	0.718
Performance status
0-1	110	1			1
2-3	42	1.033	0.721-1.480	0.860	1.461	0.986-2.166	0.059
Driver gene EGFR/ALK/c-met
Wild type	120	1			1
Mutant type	32	0.830	0.558-1.235	0.358	0.834	0.536-1.300	0.423
Number of metastases
≤3	82	1			1
>3	70	1.044	0.756-1.441	0.796	1.091	0.762-1.561	0.634
History of tumor surgery
No	86	1			1
Yes	66	0.813	0.586-1.128	0.214	0.734	0.509-1.059	0.099
Number of previous treatment lines
3	89	1			1
>3	63	1.147	0.828-1.588	0.409	1.020	0.710-1.466	0.913
Pre-NLR
≤3.41	78	1			1
>3.41	74	1.454	1.054-2.008	0.015	1.642	1.147-2.350	0.006
Pre-PLR
≤205.63	86	1			1
>205.63	66	1.654	1.192-2.296	0.001	1.698	1.185-2.433	0.003
Post-NLR variation
Decrease	80	1			1
Rise	72	1.531	1.108-2.115	0.006	1.632	1.140-2.337	0.007
Post-PLR variation
Decrease	95	1			1
Rise	57	0.982	0.706-1.366	0.915	1.125	0.778-1.625	0.532